NR 567 Exam 1 V2 | NR 567 Advanced
Pharmacology for the AGACNP | Actual
Q&A with Rationale (NR567 Exam 1) |
Chamberlain College of Nursing
1. When evaluating the pharmacokinetics of a new intravenous medication, the AGACNP knows
that bioavailability (F) is defined as:
A. The fraction of the administered dose that reaches the systemic circulation in an
unchanged form.
B. The volume of plasma from which the drug is completely cleared per unit of time.
C. The rate at which a drug is excreted by the kidneys.
D. The time required for the plasma concentration of a drug to decrease by fifty percent.
Answer: A
Rationale: Bioavailability represents the percentage of an administered drug dose that enters
the systemic circulation to produce a therapeutic effect. For drugs administered
intravenously, bioavailability is by definition 100 percent since the entire dose bypasses
absorption barriers. The AGACNP must account for bioavailability when converting
medication routes to ensure that therapeutic plasma levels are maintained during acute care
management.
,2. Which of the following factors are known to significantly influence the volume of distribution
(Vd) of a drug in a critically ill patient? Select all that apply.
A. Lipid solubility of the drug
B. Degree of plasma protein binding
C. Patient’s total body water and hydration status
D. The pH of the environment and drug ionization
E. Molecular size of the drug
F. The drug’s taste and oral palatability
Answer: A, B, C, D, E
Rationale: The volume of distribution is a theoretical volume that relates the amount of drug
in the body to the concentration of drug in the plasma. Factors such as high lipid solubility or
low protein binding allow drugs to move more easily into the tissues, thereby increasing the
calculated Vd. In the AGACNP setting, changes in capillary permeability and fluid shifts
common in sepsis can drastically alter these parameters, requiring dose adjustments.
3. An AGACNP is managing a patient on a drug with a very narrow therapeutic index. This term
signifies that:
A. The dose required for a therapeutic effect is very close to the dose that causes toxicity.
B. The drug has a high safety margin and requires minimal monitoring.
C. The drug is rapidly metabolized by the liver via Phase I reactions.
, D. The drug is only effective when administered via a continuous infusion.
Answer: A
Rationale: A narrow therapeutic index indicates that there is a small window between the
effective concentration and the toxic concentration of a drug. Medications like digoxin,
lithium, and warfarin require frequent serum level monitoring or clinical assessment to
prevent life-threatening adverse events. The AGACNP must prioritize vigilant surveillance for
patients prescribed these agents to ensure safety and efficacy.
4. During Phase II metabolism, drugs typically undergo which of the following processes to
facilitate excretion?
A. Oxidation via the Cytochrome P450 enzyme system.
B. Hydrolysis to break down complex molecular bonds.
C. Reduction reactions that occur primarily in the lungs.
D. Conjugation with polar molecules like glucuronic acid to increase water solubility.
Answer: D
Rationale: Phase II metabolism involves conjugation reactions that attach a large, polar
molecule to the drug or its Phase I metabolite. This process makes the substance more
hydrophilic, which prevents reabsorption in the renal tubules and promotes excretion in the
urine or bile. Understanding these metabolic pathways is essential for the AGACNP when
treating patients with hepatic impairment who may have reduced metabolic capacity.
Pharmacology for the AGACNP | Actual
Q&A with Rationale (NR567 Exam 1) |
Chamberlain College of Nursing
1. When evaluating the pharmacokinetics of a new intravenous medication, the AGACNP knows
that bioavailability (F) is defined as:
A. The fraction of the administered dose that reaches the systemic circulation in an
unchanged form.
B. The volume of plasma from which the drug is completely cleared per unit of time.
C. The rate at which a drug is excreted by the kidneys.
D. The time required for the plasma concentration of a drug to decrease by fifty percent.
Answer: A
Rationale: Bioavailability represents the percentage of an administered drug dose that enters
the systemic circulation to produce a therapeutic effect. For drugs administered
intravenously, bioavailability is by definition 100 percent since the entire dose bypasses
absorption barriers. The AGACNP must account for bioavailability when converting
medication routes to ensure that therapeutic plasma levels are maintained during acute care
management.
,2. Which of the following factors are known to significantly influence the volume of distribution
(Vd) of a drug in a critically ill patient? Select all that apply.
A. Lipid solubility of the drug
B. Degree of plasma protein binding
C. Patient’s total body water and hydration status
D. The pH of the environment and drug ionization
E. Molecular size of the drug
F. The drug’s taste and oral palatability
Answer: A, B, C, D, E
Rationale: The volume of distribution is a theoretical volume that relates the amount of drug
in the body to the concentration of drug in the plasma. Factors such as high lipid solubility or
low protein binding allow drugs to move more easily into the tissues, thereby increasing the
calculated Vd. In the AGACNP setting, changes in capillary permeability and fluid shifts
common in sepsis can drastically alter these parameters, requiring dose adjustments.
3. An AGACNP is managing a patient on a drug with a very narrow therapeutic index. This term
signifies that:
A. The dose required for a therapeutic effect is very close to the dose that causes toxicity.
B. The drug has a high safety margin and requires minimal monitoring.
C. The drug is rapidly metabolized by the liver via Phase I reactions.
, D. The drug is only effective when administered via a continuous infusion.
Answer: A
Rationale: A narrow therapeutic index indicates that there is a small window between the
effective concentration and the toxic concentration of a drug. Medications like digoxin,
lithium, and warfarin require frequent serum level monitoring or clinical assessment to
prevent life-threatening adverse events. The AGACNP must prioritize vigilant surveillance for
patients prescribed these agents to ensure safety and efficacy.
4. During Phase II metabolism, drugs typically undergo which of the following processes to
facilitate excretion?
A. Oxidation via the Cytochrome P450 enzyme system.
B. Hydrolysis to break down complex molecular bonds.
C. Reduction reactions that occur primarily in the lungs.
D. Conjugation with polar molecules like glucuronic acid to increase water solubility.
Answer: D
Rationale: Phase II metabolism involves conjugation reactions that attach a large, polar
molecule to the drug or its Phase I metabolite. This process makes the substance more
hydrophilic, which prevents reabsorption in the renal tubules and promotes excretion in the
urine or bile. Understanding these metabolic pathways is essential for the AGACNP when
treating patients with hepatic impairment who may have reduced metabolic capacity.
